• Decrease font size
  • Return font size to normal
  • Increase font size
U.S. Department of Health and Human Services

Post-Approval Studies (PAS)

  • Print
  • Share
  • E-mail

The FDA has the authority to require sponsors to perform a post-approval study (or studies) at the time of approval of a premarket approval (PMA), humanitarian device exemption (HDE), or product development protocol (PDP) application. Post-approval studies can provide patients, health care professionals, the device industry, the FDA and other stakeholders information on the continued safety and effectiveness (or continued probable benefit, in the case of an HDE) of approved medical devices. This database allows you to search Post-Approval Study information by applicant or device information.

Learn more...


Cont f/u of Sub in SFA Global Clin Prog

Suggest Enhancement / Report Issue | export reports to excelExport to Excel
Study Status Progress Adequate
Application Number P140010 / PAS002
Date Current Protocol Accepted 06/19/2015
Study Name Cont f/u of Sub in SFA Global Clin Prog
General Study Protocol Parameters
Study Design Prospective Cohort Study
Data Source New Data Collection
Comparison Group No Control
Analysis Type Descriptive
Study Population Transit. Adolescent B (as adults) : 18-21 yrs, Adult: >21
Detailed Study Protocol Parameters
Study Design Description Prospective cohort study of the continued follow-up of patients enrolled in the IN.PACT superficial femoral artery (SFA) Global Clinical Program (premarket cohorts and the IN.PACT Global Study).
The study population includes all IN.PACT Admiral drug-coated balloon (DCB) subjects enrolled in the IN.PACT SFA Trial, the IN.PACT SFA pharmacokinetic (PK) Sub-study, and the IN.PACT Global Study.
The IN.PACT SFA Trial was designed as a two-phase, global, multicenter, single-blind, randomized (2:1 IN.PACT Admiral DCB to percutaneous transluminal angioplasty (PTA)) trial.
The IN.PACT SFA PK Sub-study was designed to characterize the concentration level and pharmacokinetic parameters of paclitaxel in the systemic circulation over time. The sub-study was conducted concurrently with the IN.PACT SFA II phase of the IN.PACT SFA Trial in the United States.
The IN.PACT SFA Global Study was designed as a prospective, multi- center, single-arm study of consecutively enrolled patients treated for atherosclerotic disease of the SFA and/or
popliteal artery (PA) with the IN.PACT Admiral DCB.

Study Population Description The study population includes all IN.PACT Admiral DCB subjects enrolled in the IN.PACT SFA Trial, the IN.PACT SFA PK Sub- study, and the IN.PACT Global Study.

Sample Size There are at least 1,600 IN.PACT Admiral DCB subjects, including 220 DCB subjects from the IN.PACT SFA Trial, 25 DCB subjects from the IN.PACT SFA PK Sub-study, and 1,400 DCB subjects from the IN.PACT Global Study.

Data Collection Key safety and effectiveness endpoints

Through 60 months

-Major Adverse Event Composite and its individual components (All-cause mortality, clinically-driven target vessel revascularization (CD-TVR), major target limb amputation, and thrombosis at the target lesion)

-Clinically-driven target lesion revascularization (CD-TLR)

-All TLR

-All TVR

-Serious Adverse Events

At 24 and 36 months

- Primary sustained clinical improvement

- Secondary sustained clinical improvement

- Quality of Life assessment

- Walking capacity

Follow-up Visits and Length of Follow-up 5 years

Cont f/u of Sub in SFA Global Clin Prog Schedule

Report Schedule
Date Due
FDA Receipt
Applicant's Reporting Status
one year report 12/30/2015 12/18/2015 On Time
two year report 08/20/2017 08/16/2017 On Time
final report 10/01/2018 10/05/2018 Overdue/Received

Contact Us

Julie Unger
Project Manager, Post-Approval Studies Program
Food and Drug Administration
10903 New Hampshire Ave
WO66-4206v Silver Spring, MD

Phone: (301) 796-6134
Fax: (301) 847-8140

Related Links